Navigation Links
Boehringer Ingelheim's Swiss Branch Improves Sales Reporting and Efficiency with MicroStrategy Software
Date:8/26/2009

MCLEAN, Va., Aug. 26 /PRNewswire-FirstCall/ -- MicroStrategy((R)) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Boehringer Ingelheim (Schweiz) GmbH (named here as Boehringer Switzerland) has selected MicroStrategy to improve its sales reporting and efficiency. Boehringer Switzerland is the Swiss branch of the international pharmaceuticals company Boehringer Ingelheim.

Boehringer Switzerland selected MicroStrategy for reporting and analysis of sales productivity data. With MicroStrategy, sales data can now be supplied more rapidly to field sales and management, which helps the company to streamline operations. With MicroStrategy's flexible, user-friendly reports, individual users can create their own reports and work more efficiently. In addition, the reports give Boehringer Switzerland management greater insights into market data to help them plan sales activity and analyze the productivity of regional sales groups.

As part of its extensive selection process, the Boehringer Switzerland management team defined 10 Key Performance Indicators and asked selected BI providers to create several reports with this information. "MicroStrategy made an excellent impression during our evaluation process. In addition, our team in Australia has already deployed MicroStrategy for reporting and has had positive results," said Mr. Gregor Brunner, Department Manager IT of Boehringer Switzerland.

"MicroStrategy provides greater reporting capabilities than other BI suppliers and is very user-friendly," explained Alexander Herter, Business Analyst at Boehringer Switzerland and Project Manager for the evaluation of the new BI solution. "Data can be supplied rapidly and more clearly with MicroStrategy, and the reports serve as a basis for operational and strategic decisions."

"We are pleased to have the Swiss branch of Boehringer Ingelheim, one of the world's leading pharmaceutical companies, as our new customer," said Sanju Bansal, MicroStrategy's COO.

About Boehringer Switzerland

The Boehringer headquarters is in Ingelheim, Germany and the enterprise Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at www.microstrategy.com.

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Contact:
    Wende Cover
    MicroStrategy Incorporated
    703-770-1646
    wcover@microstrategy.com


'/>"/>
SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
3. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
7. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
8. Do the Swiss Have the Answer to Americas Health Care Dilemma?
9. EMH Swiss Medical Publisher Ltd. Selects Editorial Manager for Online Peer Review
10. Swissray Awarded US Government Contract
11. Swiss Res Employer Stop Loss Product Offers US Companies Cost Savings for Self-Funded Health Insurance Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... A new and improved Orgasm-Shot ... look and feel about themselves and their sexual encounters. A unique medical practice ... leakage head on with a ground breaking medical technique aimed to give women ...
(Date:6/26/2017)... ... 2017 , ... KICKICO , a protocol built on Ethereum for more ... catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will launch ... raising of funds through the power of many - has been around for about ...
(Date:6/25/2017)... ... ... lyric music video in Final Cut Pro X with ProLyric from Pixel Film Studios. Users ... to any song. ProLyric flies in the text for each section and it hovers around ... for optimal control. ProLyric makes editing any music video or text-based production easier than ever. ...
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... testing for medications in select Florida and Texas doctors' offices and clinics. This ... new application of genetic testing recognizes the role genes play in determining an ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
Breaking Medicine Technology: